ロード中...
Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases
The triple-angiokinase inhibitor nintedanib is an orally available, potent, and selective inhibitor of tumor angiogenesis by blocking the tyrosine kinase activities of vascular endothelial growth factor receptor (VEGFR) 1–3, platelet-derived growth factor receptor (PDGFR)-α and -β, and fibroblast gr...
保存先:
| 出版年: | J Pharmacol Exp Ther |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
The American Society for Pharmacology and Experimental Therapeutics
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6040086/ https://ncbi.nlm.nih.gov/pubmed/29263244 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.117.244129 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|